Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now displays a new revision tag (v3.5.3), replacing the previous v3.5.2, indicating a release update to the page's content management without altering study data. No study details or eligibility criteria appear to be changed.
    Difference
    0.1%
    Check dated 2026-04-30T18:41:22.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-16T10:51:44.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The study page now shows 'Results Submitted' instead of 'No Results Posted'.
    Difference
    0.1%
    Check dated 2026-04-09T08:28:50.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    - Revision: v3.5.0 added; Revision: v3.4.3 removed.
    Difference
    0.1%
    Check dated 2026-03-18T18:18:30.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    Revision: v3.4.3 added; revision changed from v3.4.2. No substantive changes to the study details are evident.
    Difference
    0.1%
    Check dated 2026-03-11T12:25:12.000Z thumbnail image
  7. Check
    84 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the lapse-in-government-funding notice and the older Revision: v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-11T02:38:14.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.